HALO Buybacks
13 quarter-specific issuer repurchase-cash observations normalized from SEC filings, newest first. A filed zero remains visible; a missing filing fact is never converted into zero. This page shows rows 1–13; provenance stays internal.
| Issuer profile | Period end | Type | Reported cash |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. | 2025-12-31 | Reported repurchase cash | $0.00 |
| HALOZYME THERAPEUTICS, INC. | 2024-12-31 | Reported repurchase cash | $250M |
| HALOZYME THERAPEUTICS, INC. | 2024-03-31 | Reported repurchase cash | $0.00 |
| HALOZYME THERAPEUTICS, INC. | 2023-12-31 | Reported repurchase cash | $252.3M |
| HALOZYME THERAPEUTICS, INC. | 2023-03-31 | Reported repurchase cash | $150.08M |
| HALOZYME THERAPEUTICS, INC. | 2022-12-31 | Reported repurchase cash | $1,000.00 |
| HALOZYME THERAPEUTICS, INC. | 2022-03-31 | Reported repurchase cash | $0.00 |
| HALOZYME THERAPEUTICS, INC. | 2021-12-31 | Reported repurchase cash | $160.32M |
| HALOZYME THERAPEUTICS, INC. | 2021-03-31 | Reported repurchase cash | $76.18M |
| HALOZYME THERAPEUTICS, INC. | 2020-12-31 | Reported repurchase cash | $40.15M |
| HALOZYME THERAPEUTICS, INC. | 2020-03-31 | Reported repurchase cash | $51.57M |
| HALOZYME THERAPEUTICS, INC. | 2019-12-31 | Reported repurchase cash | $200M |
| HALOZYME THERAPEUTICS, INC. | 2019-03-31 | Reported repurchase cash | $0.00 |